Background
Methods
Study design and participants
Data collection
Statistical analysis
Results
Sample description
Case Age/gender | Mutation | Comorbidities and chronic complications | Tests for SARS-CoV-2 | A1C levels | HDL levels | No-HDL levels | TG levels | Medications in use |
---|---|---|---|---|---|---|---|---|
1 16, M | AGPAT2 | DM, ↑TG, ↓ HDL, HS, nephropathy (albuminuria), peripheral neuropathy | Non-reactive | 9.7 | 29 | 120 | 384 | Insulin (7.25), MTF |
2 32, F | AGPAT2 | DM, ↑TG, ↓ HDL, SAH, CAD, HS, CKD on dialysis, peripheral neuropathy | Reactive | 6.6 | 23 | 91 | 125 | Insulin (5.8), statine |
3 37, F | AGPAT2 | DM, ↑TG, ↓ HDL, HS, nephropathy (albuminuria), peripheral neuropathy | Reactive | 9.9 | 22 | 56 | 142 | Insulin (1.71), MTF, statine |
4 42, F | AGPAT2 | DM, ↑TG, ↓ HDL, SAH, HS, retinopathy | Non-reactive | 5.6 | 25 | 96 | 191 | Insulin (1), MTF, statine |
5 24, F | AGPAT2 | DM, ↑TG, ↓ HDL, HS | Non-reactive | 5.6 | 24 | 133 | 664 | MTF, fibrate |
6 32, F | AGPAT2 | DM, ↑TG, ↓ HDL, HS, nephropathy (albuminuria), peripheral neuropathy, retinopathy | Non-reactive | 11.2 | 31 | 200 | 634 | Insulin (1.55), MTF, fibrate, statine |
7 7, F | AGPAT2 | ↑TG, ↓ HDL, HS | Reactive | 5.2 | 39 | 109 | 49 | None |
8 33, M | AGPAT2 | DM, ↑TG, ↓ HDL, HS, nephropathy (albuminuria), retinopathy | Reactive | 11.2 | 40 | 110 | 114 | Insulin (1.32), MTF |
9 7, M | AGPAT2 | ↑TG, ↓ HDL, HS | Non-reactive | 5.3 | 26 | 118 | 268 | MTF |
10 10, M | AGPAT2 | ↑TG, ↓ HDL | Non-reactive | 5 | 47 | 124 | 95 | MTF |
11 1, M | AGPAT2 | DM, ↑TG, ↓ HDL | Reactive | 5.5 | 24 | 79 | 144 | None |
12 11, F | AGPAT2 | DM, ↑TG, ↓ HDL, HS | Reactive | 8.6 | 41 | 172 | 427 | MTF |
13 13, F | AGPAT2 | DM, ↑TG, ↓ HDL, HS, peripheral neuropathy | Non-reactive | 6.8 | 24 | 123 | 436 | MTF |
14 20, M | AGPAT2 | DM, ↑ TG, ↓ HDL, HS, peripheral neuropathy | Non-reactive | 9.9 | 34 | 153 | 262 | MTF, statine |
15 26, F | AGPAT2 | DM, ↑TG, ↓ HDL, HS, nephropathy (albuminuria), retinopathy | Non-reactive | 11.4 | 37 | 198 | 635 | Insulin (1.96), MTF |
16 29, F | AGPAT2 | DM, ↑TG, ↓ HDL, HS, nephropathy (albuminuria), peripheral neuropathy, retinopathy | Non-reactive | 5.5 | 20 | 121 | 891 | Insulin (3.24), MTF, fibrate, statine |
17 41, M | AGPAT2 | DM, ↑TG, ↓ HDL, HS, retinopathy | Non-reactive | 7.3 | 26 | 162 | 524 | Insulin (1.41), MTF |
18 9, M | BSCL2 | ↑TG, ↓ HDL | Reactive | 5 | 27 | 129 | 289 | MTF |
19 12, F | BSCL2 | DM, ↑TG, ↓ HDL, HS, nephropathy (albuminuria), peripheral neuropathy | Non-reactive | 8.2 | 33 | 127 | 526 | MTF |
20 16, F | BSCL2 | DM, ↑TG, ↓ HDL, HS, peripheral neuropathy | Reactive | 11 | 33 | 138 | 141 | Insulin (2.58), MTF |
21 21, M | BSCL2 | DM, ↑TG, ↓ HDL, HS, nephropathy (albuminuria), peripheral neuropathy | Non-reactive | 10.4 | 45 | 146 | 139 | Insulin (1.53), MTF |
22 35, F | BSCL2 | DM, ↓ HDL, HS | Non-reactive | 5.6 | 29 | 83 | 80 | Insulin (0.39), MTF, statine |
SARS-CoV-2 infection outcomes in CGL patients
SARS-CoV-2+ | SARS-CoV-2- | p | |
---|---|---|---|
Patients, n | 8 (36.3%) | 14 (63.6%) | |
Female, n (%) | 5 (62.5%) | 8 (57.1%) | > 0.999 |
Age (years), median (min-max) | 13.5 (1–37) | 22.5 (7–42) | 0.355 |
Under 18 years, n (%) | 5 (62.5%) | 5 (35.7%) | 0.378 |
Mutation | |||
AGPAT2, n (%) | 6 (75%) | 10 (71.4%) | > 0.999 |
BSCL2, n (%) | 2 (25%) | 4 (28.6%) | > 0.999 |
Metabolic profile | |||
A1C median (min–max) | 7.6 (5–11.2) | 7.05 (5–11.4) | 0.86 |
TC median (min–max) | 149 (78–213) | 158.5 (112–235) | 0.159 |
HDL median (min–max) | 30 (22–41) | 29 (20–47) | 0.909 |
Non-HDL median (min–max) | 109.5 (56–172) | 125.5 (83–200) | 0.111 |
TG median (min–max) | 141.5 (49–427) | 410 (80–891) | 0.023 |
Metabolic control | |||
A1C > 7.0%, n (%)** | 4 (66%) | 7 (58%) | > 0.999 |
No-HDL > 100, n (%) | 5 (62.5%) | 12 (85.7%) | 0.5492 |
Hypertrygliceridemia*, n (%) | 4 (50%) | 10 (71.4%) | 0.3864 |
Comorbidities | |||
DM, n (%) | 6 (75%) | 12 (85.7%) | 0.602 |
Duration of DM (years), median (min–max) | 6.5 (0.1-19) | 11 (0.1-21) | 0.501 |
Low HDL, n (%) | 8 (100%) | 14 (100%) | – |
Hypertriglyceridemia, n (%) | 8 (100%) | 13 (92.8%) | > 0.999 |
Arterial hypertension, n (%) | 1 (12.5%) | 1 (7%) | > 0.999 |
Medicines in use | |||
Insulin, n (%) | 4 (50%) | 8 (57.2%) | > 0.999 |
Daily dose of insulin median, IU/kg/day | 2.1 (1.3–5.8) | 1.5 (0.4-7.2) | 0.57 |
Metformin, n (%) | 5 (62.5%) | 13 (92.8%) | 0.076 |
Fibrate, n (%) | 0 | 2 (14.3%) | 0.5152 |
Statine, n (%) | 2 (25%) | 5 (35.7%) | > 0.999 |
Clinical symptoms*** | |||
Fever, n (%) | 3 (37.5%) | 3 (21.4%) | 0.6244 |
Cough, n (%) | 1 (12.5%) | 2 (14.2%) | > 0.999 |
Sore throat, n (%) | 1 (12.5%) | 5 (35.7) | 0.3512 |
Myalgia, n (%) | 0 | 3 (21.4%) | 0.2727 |
Fatigue, n (%) | 0 | 0 | – |
Dyspnea, n (%) | 1 (12.5%) | 2 (14.2%) | > 0.999 |
Chest pain, n (%) | 2 (25%) | 1 (7.1%) | 0.5273 |
Nausea, n (%) | 3 (37.5%) | 1 (7.1%) | 0.1167 |
Diarrhea, n (%) | 3 (37.5%) | 3 (21.4%) | 0.6244 |
No symptoms, n (%) | 5 (62.5%) | 6 (42.8%) | 0.6594 |
Outcomes | |||
Hospitalization, n (%) | 0 | ||
Death, n (%) 0 | 0 |